Trial Profile
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 13 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 13 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.